1. Tavakoli A, Vahdat K, Keshavarz M. Novel coronavirus disease 2019 (COVID-19): an emerging infectious disease in the 21st century. ISMJ 2020; 22(6): 432-50. ## [DOI:10.29252/ismj.22.6.432]

2. MacKenzie D. Covid-19 goes global. Elsevier: Available; 2020; 35-7. From:https://www.sciencedirect.com/science/article/pii/S0262407920304243. ##

3. Mirmohammadkhani M, Paknazar F, Rashidy-pour A L. Evaluation of the epidemiological pattern of COVID-19 applying basic reproduction number: An educational review article. Koomesh 1399; 22(3): 373-9. ## [DOI:10.29252/koomesh.22.3.373]

4. Chen D, Zhou T. Control efficacy on COVID-19. ArXiv Preprint ArXiv 2003; 00305: 2020. ##

5. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology 2020; 296(2): E15-25. ## [DOI:10.1148/radiol.2020200490] [PMID] []

6. Organization WH. Weekly epidemiological update on COVID-19 - 21 December 2022. 2022. ##

7. Barber RM, Sorensen RJ, Pigott DM, Bisignano C, Carter A, Amlag JO, et al. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021; a statistical analysis. The Lancet 2022; 399(10344): 2351-80.##

8. Golpour M, Valadan R, Zargari M, Mousavi T. Review of the major SARS-CoV-2 mutations in different variants and their function. Journal of Mazandaran University of Medical Sciences 2021; 31(200): 187-98.##

9. Kashani A, Mehr M, Elkhichi P. Challenges of laboratory sampling and diagnosis of SARS-CoV-2 virus of disease (COVID-19). Urmia Medical Journal 2021; 32(3): 156-74. ##

10. Education MoHaM. National program to establish and expand immunization of Covid 19 in Iran, Tehran. ##

11. Heidari M, Jafari H. Challenges of COVID-19 vaccination in Iran: In the fourth wave of pandemic spread. Prehospital and Disaster Medicine 2021; 36(5): 659-60. ## [DOI:10.1017/S1049023X21000777] [PMID] []

12. Bagheri Sheykhangafshe F, Fathi-Ashtiani A. Priority of the elderly and patients with chronic diseases in COVID-19 vaccination: Letter to Editor. Journal of Birjand University of Medical Sciences 2021; 28(3): 302-6. ## [DOI:10.32592/JBirjandUnivMedSci.2021.28.3.109]

13. Miles LW, Williams N, Luthy KE, Eden L. Adult vaccination rates in the mentally ill population: an outpatient improvement project. Journal of the American Psychiatric Nurses Association 2020; 26(2): 172-80.## [DOI:10.1177/1078390319831763] [PMID]

14. Bagheri Sheykhangafshe F. COVID-19 Vaccination: challenges and opportunities. Journal of Rafsanjan University of Medical Sciences 2022; 20(11): 1289-94. ## [DOI:10.52547/jrums.20.11.1289]

15. Kolozsvari LR, Bérczes T, Hajdu A, Gesztelyi R, Tiba A, Varga I, et al. Predicting the epidemic curve of the coronavirus (SARS-CoV-2) disease (COVID-19) using artificial intelligence. MedRxiv 2021; 2020: 22: 2020-04.## [DOI:10.1101/2020.04.17.20069666]

16. Murray CJ, COVID-19 will continue but the end of the pandemic is near. The Lancet 2022; 399(10323): 417-419. ## [DOI:10.1016/S0140-6736(22)00100-3] [PMID]

17. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study. The Lancet 2022; 399(10332): 1303-1312.## [DOI:10.1016/S0140-6736(22)00462-7] [PMID]

18. Wan J, Cazer CL, Clarkberg ME, Henderson SG, Lee SE, Meredith G, et al. Boosters protect SARS-CoV-2 infections in young adults during an Omicron-predominant period. medRxiv, 2022. ##

19. Chemaitelly H, Ayoub H, AlMukdad S, Coyle P, Tang P, Yassini HM, et al. Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar :a retrospctive cohort study. Lancet microb 2022; 3(12): e944-e955. ## [DOI:10.1016/S2666-5247(22)00287-7] [PMID]

20. Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. New England Journal of Medicine 2022; 386(17): 1603-1614.## [DOI:10.1056/NEJMoa2201688] [PMID] []

21. Arbel RR, Sergienko M, Friger A, Peretz T. Beckenstein S . Second booster vaccine and covid-19 mortality in adults 60 to 100 years old. Preprint from Research Square, 2022. ## [DOI:10.21203/rs.3.rs-1478439/v1]